- Third quarter 2016 Revenue of $518,000 compared with $102,000 in the prior year's third quarter, underscoring the Company's progress growing NexoBrid ® sales;
- U.S. Phase 3 clinical trial protocol for NexoBrid to debride severe burns amended to increase the Total Body Surface Area (TBSA) of burn patients eligible for the study from 15% to 30%; and
- Multiple oral and poster presentations highlighting EscharEx ® and NexoBrid's innovative, effective and fast enzymatic debriding of severe burns and chronic wounds presented at the 18 th Congress of the International Society for Burn Injuries (ISBI).
YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and nine months ended September 30, 2016. Highlights of the third quarter of 2016 include: